CLINICAL TRIALS PROFILE FOR CONTRAVE
✉ Email this page to a colleague
All Clinical Trials for CONTRAVE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00563563 ↗ | A Study of Naltrexone SR/ Bupropion SR in Overweight and Obese Subjects Who Are Nicotine-Dependent | Completed | Orexigen Therapeutics, Inc | Phase 2 | 2007-10-01 | The purpose of this study is to determine whether a combination of naltrexone SR and bupropion SR is safe and effective in the treatment of nicotine-dependence in overweight and obese subjects. |
| NCT01601704 ↗ | Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study) | Terminated | Orexigen Therapeutics, Inc | Phase 3 | 2012-06-01 | The purpose of this study is to determine the effects of NB relative to placebo on major adverse cardiovascular events (MACE) such as cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in overweight and obese subjects who are at a higher risk of having these events because they have diabetes and/or other cardiovascular risk factors. |
| NCT02259179 ↗ | Bioequivalence Study Comparing Naltrexone SR/Bupropion SR Trilayer Tablets From Two Manufacturers | Completed | Orexigen Therapeutics, Inc | Phase 1 | 2014-09-01 | This is a Phase 1, open-label, randomized, single-dose, 2-way crossover study in healthy adult subjects to assess the bioequivalence of naltrexone SR/bupropion SR combination trilayer tablets prepared at two different manufacturing sites. The pharmacokinetics of the two drug products will be evaluated separately in the fed and fasted state. |
| NCT02638129 ↗ | Naltrexone/Bupropion Cardiovascular Outcomes Study | Terminated | Orexigen Therapeutics, Inc | Phase 4 | 2016-01-01 | The purpose of this study is to evaluate cardiovascular (CV) safety of naltrexone hydrochloride (HCl) and bupropion HCl extended release combination (NB) compared with placebo and rule out excess risk of major adverse cardiovascular events (MACE) when given in combination with standard of care in overweight and obese participants with documented history of CV disease. |
| NCT03045341 ↗ | Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment | Active, not recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2/Phase 3 | 2017-02-27 | This study will test the effectiveness and relative efficacy of behavioral and pharmacologic treatments, alone and in combination, for the treatment of binge eating disorder (BED) in patients with obesity. This is an acute treatment comparing behavioral weight loss alone or in combination with naltrexone/bupropion medication. |
| NCT03045341 ↗ | Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment | Active, not recruiting | Yale University | Phase 2/Phase 3 | 2017-02-27 | This study will test the effectiveness and relative efficacy of behavioral and pharmacologic treatments, alone and in combination, for the treatment of binge eating disorder (BED) in patients with obesity. This is an acute treatment comparing behavioral weight loss alone or in combination with naltrexone/bupropion medication. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CONTRAVE
Condition Name
Clinical Trial Locations for CONTRAVE
Trials by Country
Clinical Trial Progress for CONTRAVE
Clinical Trial Phase
Clinical Trial Sponsors for CONTRAVE
Sponsor Name
